QualityStocksNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Inks MOU with BioCan Technologies
Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP), a pharmaceutical and IP development firm, this morning announced that it has entered into a Memorandum of Understanding (“MOU”) with BioCan Technologies Inc. of Calgary, Alberta to collaborate exclusively to conduct additional investigations of cannabis strains being developed by Veritas’ research arm, Cannevert Therapeutics Ltd. (“CTL”). Optimizing the genetics of the cannabis plants for scientific and clinical testing over the next two years is the company’s primary focus during the collaboration. Definitive agreements relating to the MOU are anticipated to be signed by July 31, 2018. “BioCan’s geneticists will help CTL scientists…